Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
| Autor: | Rocconi, Rodney P., Grosen, Elizabeth A., Ghamande, Sharad A., Chan, John K., Barve, Minal A., Oh, Jonathan, Tewari, Devansu, Morris, Peter C., Stevens, Erin E., Bottsford-Miller, Justin N., Tang, Min, Aaron, Phylicia, Stanbery, Laura, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Manning, Luisa, Nemunaitis, John, Shanahan, David, Slomovitz, Brian M. |
|---|---|
| Zdroj: | Obstetrical & Gynecological Survey; Mar2021, Vol. 76 Issue 3, p151-152, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|